The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort

BACKGROUND: The clinical experience with protease-inhibitor (PI) triple regimen appears disappointing regarding effect, side effects, high work load, and costs. This real-world study evaluates baseline and emerging resistance-associated substitutions (RASs) and their significance for treatment outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjellin, Midori, Wesslén, Terése, Löfblad, Erik, Lennerstrand, Johan, Lannergård, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901468/
https://www.ncbi.nlm.nih.gov/pubmed/29536805
http://dx.doi.org/10.1080/03009734.2018.1441928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901468/
https://www.ncbi.nlm.nih.gov/pubmed/29536805
http://dx.doi.org/10.1080/03009734.2018.1441928

Ejemplares similares